Edmund Harrigan - May 29, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Director
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
May 29, 2024
Transactions value $
$0
Form type
4
Date filed
5/31/2024, 06:00 PM
Previous filing
Apr 2, 2024
Next filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +6.65K +35.01% 25.7K May 29, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -6.65K -100% $0.00* 0 May 29, 2024 Common Stock 6.65K Direct F1, F2
transaction ACAD Director Stock Options (Right to Buy) Award $0 +16K $0.00 16K May 29, 2024 Common Stock 16K $14.62 Direct F3
transaction ACAD Restricted Stock Units Award $0 +9.39K $0.00 9.39K May 29, 2024 Common Stock 9.39K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2 The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held.
F3 The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4 The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.